JUNE 2, 2024 by The Endocrine Society Credit: Pixabay/CC0 Public DomainMost patients with thyroid eye disease treated with teprotumumab didn’t require additional treatment nearly two years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, and published in the journal Thyroid. “Thyroid eye disease is a...
